PO.TB07.01 · 肿瘤生物学

研究foxo1维持干细胞的能力

Investigating the ability of foxo1 to maintain stem cells

海报缩略图:研究foxo1维持干细胞的能力
编号 844 展板 23 时间 4/19 02:00–05:00 区域 Section 33 主讲 Stella Rios, BS
分会场 Stem Cell Plasticity and Lineage Reprogramming in Cancer
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Stella Aime Rios, Megan E. Keniry

College of Sciences, University of Texas Rio Grande Valley, Edinburg, TX

摘要 Abstract

中文摘要
背景:我们的团队发现FOXO转录因子驱动癌症中的干性基因表达以促进侵袭性。我们团队及其他团队的工作证明,FOXO因子在包括癌症、胚胎、造血和神经等背景下普遍维持干细胞。我们目前的努力正在阐明FOXO因子阻止分化以维持干细胞的分子基础。在本项目中,我们采用成肌细胞作为一个有价值的模型,以考察Foxo1如何维持干细胞。成肌细胞中受Foxo1调控的基因与其在胶质母细胞瘤和基底样乳腺癌干细胞中的靶标高度平行,包括白血病抑制因子Lif等靶标——Lif编码一种可阻止分化的细胞因子。理解Foxo1如何维持干细胞至关重要,因为它有可能揭示新的治疗选择,靶向参与癌症进展和化疗耐药的基本生物学过程。 方法:对C2C12成肌细胞进行RNAi以构建Foxo1敲低和对照细胞系,随后使用qRT-PCR评估参与分化、增殖和肌纤维类型的靶基因。利用荧光显微镜研究Foxo1敲除细胞与对照组之间肌动蛋白丝和细胞核的结构差异。我们的初步工作包括使用qRT-PCR研究候选基因。我们目前正采用基因组学方法研究Foxo1在成肌细胞/干细胞分化中的作用。 结果:在Foxo1敲除细胞中,Lif表达显著下降,提示分化。Igfbp1、Socs1和Socs2等基因的下调表明其可能受Foxo1直接或间接激活,对细胞生长和细胞因子信号传导有影响。此外,Pepck的下调以及能量代谢通路的调节提示代谢状态发生改变。Stat1和Wnt3的下调意味着促进增殖的通路受到破坏而转向有利于分化。这与Foxo1敲除细胞中细胞核和肌动蛋白丝丰度增加的观察结果一致,反映了肌肉分化和肌管形成的增强。 结论:Foxo1通过基因表达调控细胞动态的参与是复杂而动态的,影响分化和增殖,细胞骨架发生显著变化促进成肌细胞融合和分化。深入了解Foxo1与靶基因之间的关系将阐明决定干细胞和祖细胞分化状态的潜在保守作用。我们预期该模型系统将使我们能够洞悉维持干细胞的基本机制,最终靶向已知会引发复发和化疗耐药的癌症干细胞。
查看英文原文 English abstract
Background : Our group discovered that FOXO transcription factors drive stem gene expression in cancer to promote aggressiveness. Work by our group and others demonstrated that FOXO factors universally maintain stem cells including in cancer, embryonic, hematogenic and neuronal contents. Our current efforts are delineating the molecular underpinnings by which FOXO factors halt differentiation to maintain stem cells. In this project, we are employing myoblasts as a valuable model to examine how Foxo1 maintains stem cells. Foxo1-regulated genes in myoblasts closely parallel its targets in glioblastoma and basal breast cancer stem cells, including targets such as Leukemia Inhibitory Factor , Lif, encoding a cytokine that prevents differentiation. Understanding how Foxo1 maintains stem cells is crucial, as it holds the potential to uncover new therapeutic options that could target the fundamental biological processes involved in cancer progression and chemotherapeutic resistance. Methods : RNAi was performed on C2C12 myoblasts cells to create Foxo1 knockdown and control lines, followed by assessment of target genes involved in differentiation, proliferation, and muscle fiber types using qRT-PCR. Fluorescent microscopy was utilized to investigate the structural differences in actin filaments and nuclei between Foxo1 knockout cells and the control group. Our initial work, including investigating candidate genes using qRT-PCR. We are currently taking genomics approaches to investigate the role of Foxo1 in myoblast/stem cell differentiation. Results: ​ ​In Foxo1 knockout cells, there was a notable decrease in Lif expression, suggesting differentiation.​ Downregulation of genes like Igfbp1 , Socs1 , and Socs2 indicates possible direct or indirect activation by Foxo1 , with implications for cell growth and cytokine signaling. Additionally, downregulation of Pepck and the modulation of energy metabolism pathways suggest altered metabolic states. The downregulation of Stat1 and Wnt3 implies disruptions in pathways that promote proliferation to favor differentiation. This aligns with observations of increased nuclei and actin filament abundance in Foxo1 knockout cells, reflecting enhanced muscle differentiation and myotube formation. Conclusion: Foxo1's involvement in regulating cellular dynamics through gene expression is complex and dynamic, impacting differentiation and proliferation, with notable changes in the cytoskeleton facilitating myoblast fusion and differentiation. Gaining insights into the relationship between Foxo1 and target genes will clarify potentially conserved roles that determine the differentiation status of stem and progenitor cells. We are anticipate that this model system will allow us to glean fundamental mechanisms that maintain stems cells to ultimately target cancer stem cells, which are known to trigger recurrence and chemotherapeutic resistance.
利益披露 Disclosure
S. A. Rios, None.. M. E. Keniry, None.

← 返回 AACR 2026 检索